To the Editor The treatment landscape of advanced hepatocellular carcinoma (HCC) has significantly changed in recent years. We applaud that Sonbol and colleagues1 conducted a systematic review and network meta-analysis providing a more systematic understanding of advanced HCC treatment options, irrespective of first-line or second-line setting. Herein, we raise several concerns.